{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:40Z","timestamp":1789135960250,"version":"build-2803163510"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tuberculosis (TB) management faces persistent challenges, particularly in optimizing treatment. Therapeutic drug monitoring (TDM) using high-performance liquid chromatography (HPLC) has emerged as a precise and sensitive method for adjusting drug dosages and improving therapeutic outcomes. This review assesses the recent advancements and underscores the role of HPLC in TDM to enhance treatment efficacy and mitigate drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PubMed, Web of Science, and Scopus were comprehensively searched to identify studies using HPLC for the TDM of first-line TB drugs in human plasma. Studies were rigorously screened to minimize bias and align with the review's objectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twelve studies involving 750 patients across 7 countries met the inclusion criteria. These studies showcased diverse populations, including pediatric and adult groups undergoing treatment for pulmonary and extrapulmonary TB. Analytical methods varied widely, with studies using different stationary phases (C18 and C8), mobile phases, elution modes (gradient and isocratic), flow rates (0.8\u20131.5 mL\/min), and injection volumes. The review examined key first-line anti-TB drugs, including isoniazid, rifampicin, pyrazinamide, and ethambutol, under varied laboratory conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This review highlights the diversity in study designs, patient populations, and chromatographic techniques for TDM of first-line anti-TB drugs. The findings emphasize the need for standardized HPLC protocols to optimize TDM practices for first-line TB drugs. Harmonizing analytical methodologies may enhance drug efficacy and reduce treatment-related toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001480","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:00:09Z","timestamp":1781118009000},"page":"562-571","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["High-Performance Liquid Chromatography for the Therapeutic Drug Monitoring of First-Line Antituberculosis Drugs: A Comprehensive Review"],"prefix":"10.1097","volume":"48","author":[{"given":"Youssra","family":"Metarfi","sequence":"first","affiliation":[{"name":"Biomedical and Translational Research Laboratory, Faculty of Medicine Pharmacy and Dental Medicine, Sidi Mohammed Ben Abdellah University, Fez, Morocco;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Ben Khadda","sequence":"additional","affiliation":[{"name":"Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine Pharmacy and Dental Medicine, Sidi Mohammed Ben Abdellah University, Fez, Morocco;"},{"name":"Laboratory of Bioresources, Biotechnology, Ethnopharmacology and Health, Faculty of Medicine and Pharmacy of Oujda, University Mohammed Premier, Oujda, Morocco;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissal","family":"Chellal","sequence":"additional","affiliation":[{"name":"Biomedical and Translational Research Laboratory, Faculty of Medicine Pharmacy and Dental Medicine, Sidi Mohammed Ben Abdellah University, Fez, Morocco;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem Karhate","family":"Andaloussi","sequence":"additional","affiliation":[{"name":"Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine Pharmacy and Dental Medicine, Sidi Mohammed Ben Abdellah University, Fez, Morocco;"},{"name":"Department of Pneumology - CHU Hassan II, Fez, Morocco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"Amara","sequence":"additional","affiliation":[{"name":"Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine Pharmacy and Dental Medicine, Sidi Mohammed Ben Abdellah University, Fez, Morocco;"},{"name":"Department of Pneumology - CHU Hassan II, Fez, Morocco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Achour","sequence":"additional","affiliation":[{"name":"Biomedical and Translational Research Laboratory, Faculty of Medicine Pharmacy and Dental Medicine, Sidi Mohammed Ben Abdellah University, Fez, Morocco;"},{"name":"Laboratory of Pharmacology and Toxicology, - CHU Hassan II, Fez, Morocco."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/pharmaceutics16091138","article-title":"Development of simultaneous drug concentration measurement method using an automated pretreatment liquid chromatography\/tandem mass spectrometry system for therapeutic drug monitoring","volume":"16","author":"Sato","year":"2024","journal-title":"Pharmaceutics"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/pharmaceutics15041255","article-title":"Profiling docetaxel in plasma and urine samples from a pediatric cancer patient using ultrasound-assisted dispersive liquid\u2013liquid microextraction combined with LC\u2013MS\/MS","volume":"15","author":"Maliszewska","year":"2023","journal-title":"Pharmaceutics"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"124996","DOI":"10.1016\/j.talanta.2023.124996","article-title":"Overview of therapeutic drug monitoring and clinical practice","volume":"266","author":"Fang","year":"2024","journal-title":"Talanta"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"100444","DOI":"10.1016\/j.jctube.2024.100444","article-title":"Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis","volume":"36","author":"Maranchick","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis."},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/9781118681121.ch23","article-title":"A comprehensive review on mycobacterium tuberculosis targets and drug development from a structural perspective","author":"Pedelacq","year":"2020","journal-title":"Struct Biol Drug Discov Methods Tech Pract."},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3389\/fchem.2019.00819","article-title":"Uncovering the resistance mechanism of Mycobacterium tuberculosis to rifampicin due to RNA polymerase H451D\/Y\/R mutations from computational perspective","volume":"7","author":"Zhang","year":"2019","journal-title":"Front Chem."},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijmyco.2014.08.003","article-title":"Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug","volume":"3","author":"Jena","year":"2014","journal-title":"Int J Mycobacteriol"},{"key":"R9-20260911","first-page":"196","article-title":"Drug-target genes and their spontaneous mutations associated with resistance to first-line, second-line, third-line, novel and repurposed anti-tuberculosis drugs in Mycobacterium tuberculosis resistant strains","volume":"8","author":"Mumena","year":"2022","journal-title":"IP Int J Med Microbiol Trop Dis."},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"102377","DOI":"10.1016\/j.tice.2024.102377","article-title":"Molecular mechanisms underlying cisplatin-induced nephrotoxicity and the potential ameliorative effects of essential oils: a comprehensive review","volume":"88","author":"Patel","year":"2024","journal-title":"Tissue Cell"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"61","DOI":"10.52711\/2231-5675.2023.00011","article-title":"A review on high performance liquid chromatography (HPLC)","volume":"13","author":"Kamble","year":"2023","journal-title":"Asian J Pharm Anal."},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"39","DOI":"10.69613\/t4nhz921","article-title":"Advances in high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC)","volume":"2","author":"Pandreka","year":"2024","journal-title":"J Pharma Insights Res."},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1365\/s10337-005-0549-0","article-title":"Therapeutic monitoring of isoniazid, pyrazinamide and rifampicin in tuberculosis patients using LC","volume":"61","author":"Unsalan","year":"2005","journal-title":"Chromatographia"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3390\/pharmaceutics15112543","article-title":"A single-run HPLC\u2013MS multiplex assay for therapeutic drug monitoring of relevant first-and second-line antibiotics in the treatment of drug-resistant tuberculosis","volume":"15","author":"K\u00f6hler","year":"2023","journal-title":"Pharmaceutics"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpha.2023.09.009","article-title":"Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management","volume":"14","author":"Thu","year":"2024","journal-title":"J Pharm Anal."},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/chromsci\/bmae023","article-title":"Development and validation of a simple high-pressure liquid chromatography-ultraviolet detection method for simultaneous quantitation of first-line anti-tuberculosis drugs in formulations of fixed-dose combination","volume":"62","author":"Vilvamani","year":"2024","journal-title":"J Chromatogr Sci."},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/s12889-021-10698-9","article-title":"Knowledge about tuberculosis, treatment adherence and outcome among ambulatory patients with drug-sensitive tuberculosis in two directly-observed treatment centres in Southwest Nigeria","volume":"21","author":"Adisa","year":"2021","journal-title":"BMC Public Health"},{"key":"R20-20260911","first-page":"1907","article-title":"Therapeutic drug monitoring in pediatric patients treated with anti-tuberculosis medications by high performance liquid chromatography","volume":"26","author":"Okuyan","year":"2022","journal-title":"J Res Pharm."},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12879-021-06764-7","article-title":"Real - life isoniazid and rifampicin plasma concentrations in children: a tool for therapeutic drug monitoring of tuberculosis","volume":"21","author":"Tersigni","year":"2021","journal-title":"BMC Infect Dis."},{"key":"R22-20260911","first-page":"674","article-title":"Development and validation of HPLC method for finding isoniazid plasma levels in TB patients with its quantification in FDC therapy","volume":"13","author":"Laique","year":"2019","journal-title":"PJMHS"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5114\/hivar.2018.76367","article-title":"Anti-tuberculosis drug concentrations and treatment outcomes among HIV-infected patients with tuberculosis","volume":"17","author":"Baniasadi","year":"2018","journal-title":"HIV AIDS Rev."},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4103\/ijmr.IJMR_1961_16","article-title":"Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients","volume":"147","author":"Kumar","year":"2018","journal-title":"Indian J Med Res."},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijantimicag.2017.12.004","article-title":"International Journal of Antimicrobial Agents Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India","volume":"51","author":"Ranjalkar","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"020031","DOI":"10.1063\/1.4953956","article-title":"Validation of pyrazinamide in human plasma using HPLC-Uv for therapeutic drug monitoring","volume":"1746","author":"Mulyani","year":"2016","journal-title":"AIP Conf Proc"},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"020030","DOI":"10.1063\/1.4953955","article-title":"Validation of isoniazid for therapeutic drug monitoring in human plasma by high-performance liquid chromatography","volume":"1746","author":"Jaikishin","year":"2016","journal-title":"AIP Conf Proc"},{"key":"R28-20260911","first-page":"1735","article-title":"Simultaneous determination of isoniazid, pyrazinamide and rifampin in human plasma by high-performance liquid chromatography and UV detection","volume":"18","author":"Dasht Bozorg","year":"2019","journal-title":"Iran J Pharm Res."},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/bmc.3778","article-title":"Determination of rifampicin in human plasma by high\u2014performance liquid chromatography coupled with ultraviolet detection after automatized solid \u2013 liquid extraction","volume":"30","author":"Louveau","year":"2016","journal-title":"Biomed.Chromatogr."},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/FTD.0000000000001149","article-title":"Effect of metformin on plasma exposure of rifampicin, isoniazid, and pyrazinamide in patients on treatment for pulmonary tuberculosis","volume":"46","author":"Kumar","year":"2024","journal-title":"Ther Drug Monit."},{"key":"R31-20260911","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijtb.2017.08.004","article-title":"Plasma levels of rifampicin and pyrazinamide with pre and post meal administration in tuberculosis patients","volume":"65","author":"Sharma","year":"2018","journal-title":"Indian J Tuberc."},{"key":"R32-20260911","first-page":"17","article-title":"Validation of HPLC methods for determination of isoniazid, rifampicin, pyrazinamide, and ethambutol in a fixed-dose combination antituberculosis","volume":"13","author":"Jongrungruangchok","year":"2015","journal-title":"Interprofessional J Heal Sci."},{"key":"R33-20260911","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1039\/D1AY01414E","article-title":"Development and validation of simple and sensitive HPLC-UV method for ethambutol hydrochloride detection following transdermal application","volume":"14","author":"Anjani","year":"2022","journal-title":"Anal Methods"},{"key":"R34-20260911","doi-asserted-by":"crossref","first-page":"a017871","DOI":"10.1101\/cshperspect.a017871","article-title":"Tuberculosis and HIV coinfection","volume":"5","author":"Bruchfeld","year":"2015","journal-title":"Cold Spring Harb Perspect Med."},{"key":"R35-20260911","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cmi.2015.05.002","article-title":"Optimization of dosing regimens and dosing in special populations","volume":"21","author":"Sime","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"R36-20260911","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1517\/17425255.2014.895813","article-title":"Understanding pharmacokinetics to improve tuberculosis treatment outcome","volume":"10","author":"Reynolds","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R37-20260911","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4046\/trd.2015.78.2.47","article-title":"Diagnosis and treatment of extrapulmonary tuberculosis","volume":"78","author":"Lee","year":"2015","journal-title":"Tuberc Respir Dis (Seoul)."},{"key":"R38-20260911","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/molecules25174026","article-title":"Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM)","volume":"25","author":"Tuzimski","year":"2020","journal-title":"Molecules"},{"key":"R39-20260911","doi-asserted-by":"crossref","first-page":"119846","DOI":"10.1016\/j.cca.2024.119846","article-title":"Liquid chromatography-tandem mass spectrometry in clinical laboratory protein measurement","volume":"562","author":"Ma","year":"2024","journal-title":"Clin Chim Acta"},{"key":"R40-20260911","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2007.07.005","article-title":"A rapid and sensitive HPLC\u2013MS method for the detection of plasma and cellular rifampicin","volume":"857","author":"Hartkoorn","year":"2007","journal-title":"J Chromatogr B"},{"key":"R41-20260911","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clinms.2018.10.002","article-title":"Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs","volume":"14 Pt A","author":"Kuhlin","year":"2019","journal-title":"Clin Mass Spectrom."},{"key":"R42-20260911","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R43-20260911","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.cmi.2024.06.030","article-title":"Developing clinical guidelines in the absence of rigorous clinical trials. Challenges in balancing the need for guidance and low-quality evidence","volume":"30","author":"Humphreys","year":"2024","journal-title":"Clin Microbiol Infect."},{"key":"R44-20260911","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2533\/chimia.2012.218","article-title":"Mass spectrometric QUAL\/QUAN approaches for drug metabolism and metabolomics","volume":"66","author":"Tonoli","year":"2012","journal-title":"Chimia (Aarau)"},{"key":"R45-20260911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2016.03.040","article-title":"Stationary phase modulation in liquid chromatography through the serial coupling of columns: a review","volume":"923","author":"Alvarez-Segura","year":"2016","journal-title":"Anal Chim Acta"},{"key":"R46-20260911","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1021\/acs.chemrev.8b00246","article-title":"Column characterization and selection systems in reversed-phase high-performance liquid chromatography","volume":"119","author":"Z\u030cuvela","year":"2019","journal-title":"Chem Rev."},{"key":"R47-20260911","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/bmc.3778","article-title":"Determination of rifampicin in human plasma by high\u2010performance liquid chromatography coupled with ultraviolet detection after automatized solid\u2013liquid extraction","volume":"30","author":"Louveau","year":"2016","journal-title":"Biomed Chromatogr."},{"key":"R48-20260911","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1556\/JPC.19.2006.2.12","article-title":"Effect of the aqueous component of the mobile phase on RP-TLC retention and its implication in the determination of lipophilicity for a series of structurally diverse drugs","volume":"19","author":"Giaginis","year":"2006","journal-title":"JPC-Journal Planar Chromatogr Mod TLC."},{"key":"R51-20260911","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1039\/C5AN02522B","article-title":"Recent advances in flow injection analysis","volume":"141","author":"Trojanowicz","year":"2016","journal-title":"Analyst"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:45Z","timestamp":1789135245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001480","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"2025-10-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}